Romano Steven J. 4

What Happened Steven J. Romano, a director of Dianthus Therapeutics (DNTH), received a grant/award on 2026-05-21 of 6,090 shares reported as a derivative (stock‑option/award) at a $0.00 exercise/purchase price (total reported value $0). This was an equity award for future ownership rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-21 (Form 4 filed 2026-05-22).
• Transaction type/code: Award/Grant (A) of derivative shares.
• Shares/rights granted: 6,090 underlying shares; reported price $0.00; reported $0 total.
• Shares owned after transaction: not specified in the provided filing.
• Vesting footnote: the shares underlying the award vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
• Timeliness: Filing appears timely (reported the day after the transaction).

Context This was a compensatory award (derivative) commonly used for director compensation/retention. It does not represent an immediate sale or cash transaction; value and tax consequences will depend on vesting and any later exercise or sale. There is no indication in the filing of a 10b5‑1 plan, tax withholding, or an immediate cashless exercise.